Table 2. Results of one-way sensitivity analyses comparing apixaban to adjusted-dose warfarin: parameters for which variations result in positive incremental cost-effectiveness ratios.

Variable	Low range	High range	Threshold value*
Apixaban drug cost, 2 weeks ($)	Dominant	35,583	106
ICH bi-weekly costs, $	26,659	Dominant	2,418
ICH hazard ratio	Dominant	12,049	0.49
Percentage of ICH that are fatal, %	Dominant	1,111	44.0
Baseline rate of ICH on warfarin, % per year	4,899	Dominant	0.70
Cost of warfarin treatment including cost of INR laboratory test, 2 weeks ($)	2,156	Dominant	6.3

ICH  =  intracranial hemorrhage; INR  =  international normalized ratio.

^*Value of variable at which apixaban was no longer found to be a dominant economic strategy.